Association Of Tight Glycemic Control With Road Crashes In Diabetic Patients

A study from Canada published this week in /PLoS// Medicine/ suggests an association between tighter glycemic control and an increased risk of a motor vehicle crash in diabetic adults. Using a population-based case control analysis over a 2 year period, Donald Redelmeier and colleagues from the University of Toronto studied the association between measured glycosylated hemoglobin (HbA1c) in diabetic drivers and the risk of a motor vehicle crash…

Go to Source

People who read this also read

• Highly-Focused, Potent Radiation Treatment Provides Targeted Tumor Control And May Improve Survival For Patients With Inoperable Lung Cancer
  Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, accordin...
• Study Shows Superior Efficacy For TAXUS(R) Express(R) Stents At One Year Compared To Bare-Metal Stents In Diabetic Patients Experiencing Heart Attack
  Boston Scientific Corporation (NYSE: BSX) announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the E...
• VEGF Trap-Eye Shows Positive Results In Phase II Study In Patients With Diabetic Macular Edema
  Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that VEGF Trap-Eye showed positive results in a Phase II study in patients with Diabetic Macular Edema (DME). The primary endpoint of the study, a statistically significant improvement in visual acuity over 24 weeks com...
• VEGF Trap-Eye Shows Positive Results In A Phase 2 Study In Patients With Diabetic Macular Edema
  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME). The primary endpoint of the study, a statistically significant improvement in visual acuity over 24 weeks com...
• Alimera Announces Positive Results From The Two Phase 3 FAME(TM) Trials Of Iluvien(R) In Patients With Diabetic Macular Edema
  Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, reported top-line results from the month 24 readout of the FAME Study. The FAME Study consists of two Phase 3 pivotal cli...